A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

By Armstrong Deborah K.   Blessing John A.   Rader Janet   Sorosky Joel I.  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 453-457

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study

By Urba Susan G.   Chansky Kari   vanVeldhuizen Peter J.   Pluenneke Robert E.   Benedetti Jacqueline K.   Macdonald John S.   Abbruzzese James L.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 91-97

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study

By Macdonald John   McCoy Sheryl   Whitehead Robert   Iqbal Syma   Wade James   Giguere Jeffrey   Abbruzzese James  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 485-487

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group

By Stuart Keith   Levy Donna E.   Anderson Tom   Axiotis Constantine A.   Dutcher Janice P.   Eisenberg Andrew   Erban John K.   Benson III Al Bowen  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

By Whitehead Robert   McCoy Sheryl   Macdonald John   Rivkin Saul   Neubauer Marcus   Dakhil Shaker   Lenz Heinz-Josef   Tanaka Michael   Abbruzzese James  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite